Track Akoustis Technologies, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Akoustis Technologies, Inc. AKTS · Stock Open Akoustis Technologies, Inc. in new tab

16.62 USD
EPS
-1.73
P/B
2.02
ROE
-26.53
Beta
1.69
Target Price
35.88 USD
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
EPS-1.73
Book Value8.23
Price to Book2.02
Debt/Equity2.36
% Insiders14.053%
Growth
Revenue Growth1.47%
Estimates
Forward P/E-7.53
Forward EPS-2.21
Target Mean Price35.88

DCF valuation

Model fair value for Akoustis Technologies, Inc. (AKTS)
Result
Sign in to run the valuation for AKTS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus Strong buy · mean target 35.88 USD (low 33.00, high 40.00) · as of 14 Nov 2026
Low 33.00
Mean 35.88
High 40.00
Price 16.62
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Akoustis Technologies, Inc. Logo Akoustis Technologies, Inc. Analysis (AKTS)

United States Information Technology Official Website Stock

Is Akoustis Technologies, Inc. a good investment? Akoustis Technologies, Inc. (AKTS) is currently trading at 16.62 USD. Market analysts have a consensus price target of 35.88 USD. This suggests a potential upside from current levels.

Earnings Schedule: Akoustis Technologies, Inc. is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -2.21.

Investor FAQ

Does Akoustis Technologies, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Akoustis Technologies, Inc.?

Akoustis Technologies, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -1.73.

Company Profile

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Exchange Ticker
NMS (United States) AKTS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion